Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-160P is a genomic pseudogene derived from the U6 small nuclear RNA (snRNA) family. U6 snRNA is an essential RNA component of the spliceosome, which catalyzes pre-mRNA splicing in the cell nucleus[1][4]. U6 snRNA itself is highly conserved and critical to cell viability, but pseudogenes such as RNU6-160P result from duplication or mutation events that render them non-functional[6]. These pseudogenes may contain sequence elements similar to the active U6 snRNA but lack genuine biological activity, often showing partial sequence homology and sometimes duplication or rearrangement[6]. Multiple U6 pseudogenes exist in the human genome, highlighting the evolutionary importance of the functional U6 snRNA gene[4][6]. RNU6-160P does not participate in splicing, is not transcribed in a regulated fashion, and has no established role in cellular biology, disease, or therapy.\n\nIn summary, RNU6-160P is a non-functional pseudogene and does not represent a valid, actionable molecular target for therapeutic intervention or drug discovery[6][4].
None applicable for drugs, as RNU6-160P is not a target for drug action.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 160, pseudogene (RNU6-160P).